Genscript Biotech Corporation (1548.HK) stock analysis

In our weekly check, Genscript Biotech Corporation is graded B (A to F). Of 22 checks on debt, profit, cash flow and trend: 15 pass, warnings: 2, red flags: 5.

About Genscript Biotech Corporation

Genscript Biotech Corporation is a Healthcare company (Biotechnology) based in Hong Kong, listed on HKSE as 1548.HK.

What our checks show for 1548.HK

Red flags

• Weak EPS growth
• The company is losing money: the net margin is -55.5%.
• The price swings a lot: 71.4% annual volatility. Expect large ups and downs.
• The stock has fallen as much as 80% from a peak. Would you have held through that?
• Return on capital (ROCE) is only 3.1%.

Warning signs

• Analysts expect earnings per share to shrink about 16.8% a year.
• Recovering from its deepest fall took about 2.3 years.

Strengths

• Net debt is only 0.3x a year of EBITDA: the balance sheet has room.
• Operating profit covers interest 14.7 times over.
• The net margin rose by 17.7 points over 5 years, to -55.5%.
• Operating cash flow is 0.61x net profit: the profit arrives as real cash.
• Analysts expect the net margin to improve by 78.8 points from today's -55.5%.
• Revenue grew 15.3% a year over the last 3 years.

Similar companies

9926.HK · MRNA · REGN · ARGX · CSL.AX · UCB.BR

Questions

What grade does Genscript Biotech Corporation (1548.HK) have?

In our weekly check, Genscript Biotech Corporation is graded B (A to F). Of 22 checks on debt, profit, cash flow and trend: 15 pass, warnings: 2, red flags: 5. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of 1548.HK stock?

This week's biggest flags for Genscript Biotech Corporation: Weak EPS growth, Thin margins, Very volatile. In total 7 of 22 checks show a warning or a red flag.

What does Genscript Biotech Corporation do?

Genscript Biotech Corporation is a Healthcare company (Biotechnology) based in Hong Kong, listed on HKSE as 1548.HK.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-24

Open the full analysis